REV1 and cancer: The injection of cisplatin plus JH-RE-06 into subcutaneous xenografted tumors in tumor-bearing mouse models significantly suppressed tumor growth and improved their prognosis compared with the injection of saline, cisplatin, or JH-RE-06 alone, indicating that targeting REV1–REV7 interactions together with DNA-damaging treatment is an effective strategy for cancer therapy [105].